Literature DB >> 16912214

Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Ying Xiong1, Hai-Ting Lu, Yongjian Li, Guang-Fu Yang, Chang-Guo Zhan.   

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) constitute a large superfamily of enzymes regulating concentrations of intracellular second messengers cAMP and cGMP through PDE-catalyzed hydrolysis. Although three-dimensional x-ray crystal structures of PDE4 and PDE5 have been reported, it is uncertain whether a critical, second bridging ligand (BL2) in the active site is H2O or HO- because hydrogen atoms cannot be determined by x-ray diffraction. The identity of BL2 is theoretically determined by performing molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations, for the first time, on the protein structures resolved by x-ray diffraction. The computational results confirm our previous suggestion, which was based on QM calculations on a simplified active site model, that BL2 in PDE4 should be HO-, rather than H2O, serving as the nucleophile to initialize the catalytic hydrolysis of cAMP. The molecular dynamics simulations and QM/MM calculations on PDE5 demonstrate for the first time that the BL2 in PDE5 should also be HO- rather than H2O as proposed in recently published reports on the x-ray crystal structures, which serves as the nucleophile to initialize the PDE5-catalyzed hydrolysis of cGMP. These fundamental structural insights provide a rational basis for future structure-based drug design targeting PDEs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912214      PMCID: PMC1544286          DOI: 10.1529/biophysj.106.086835

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  58 in total

1.  T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats.

Authors:  H Inoue; K Yano; T Ikeo; T Noto; K Kikkawa
Journal:  Eur J Pharmacol       Date:  2001-06-22       Impact factor: 4.432

Review 2.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

Authors:  Celine Mehats; Carsten B Andersen; Marcello Filopanti; S L Catherine Jin; Marco Conti
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

Review 3.  Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Circulation       Date:  2003-07-15       Impact factor: 29.690

4.  A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.

Authors:  M Aoki; M Kobayashi; J Ishikawa; Y Saita; Y Terai; K Takayama; K Miyata; T Yamada
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

Review 5.  Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3).

Authors:  E Degerman; P Belfrage; V C Manganiello
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

Review 6.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

7.  Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.

Authors:  Helmut Haning; Ulrich Niewöhner; Thomas Schenke; Mazen Es-Sayed; Gunter Schmidt; Thomas Lampe; Erwin Bischoff
Journal:  Bioorg Med Chem Lett       Date:  2002-03-25       Impact factor: 2.823

Review 8.  Cyclic nucleotide phosphodiesterases: relating structure and function.

Authors:  S H Francis; I V Turko; J D Corbin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

9.  Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.

Authors:  Akira Nagakura; Makiko Niimura; Satoshi Takeo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

10.  Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.

Authors:  Richard W Friesen; Yves Ducharme; Richard G Ball; Marc Blouin; Louise Boulet; Bernard Côté; Richard Frenette; Mario Girard; Daniel Guay; Zheng Huang; Thomas R Jones; France Laliberté; Joseph J Lynch; Joseph Mancini; Evelyn Martins; Paul Masson; Eric Muise; Douglas J Pon; Peter K S Siegl; Angela Styhler; Nancy N Tsou; Mervyn J Turner; Robert N Young; Yves Girard
Journal:  J Med Chem       Date:  2003-06-05       Impact factor: 7.446

View more
  6 in total

1.  Computational alanine scanning with linear scaling semiempirical quantum mechanical methods.

Authors:  David J Diller; Christine Humblet; Xiaohua Zhang; Lance M Westerhoff
Journal:  Proteins       Date:  2010-08-01

2.  Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.

Authors:  Bo Yang; Adel Hamza; Guangju Chen; Yan Wang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-11-15       Impact factor: 2.991

3.  Fundamental reaction pathway and free energy profile for hydrolysis of intracellular second messenger adenosine 3',5'-cyclic monophosphate (cAMP) catalyzed by phosphodiesterase-4.

Authors:  Xi Chen; Xinyun Zhao; Ying Xiong; Junjun Liu; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2011-10-05       Impact factor: 2.991

4.  Insight into the phosphodiesterase mechanism from combined QM/MM free energy simulations.

Authors:  Kin-Yiu Wong; Jiali Gao
Journal:  FEBS J       Date:  2011-06-14       Impact factor: 5.542

5.  Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.

Authors:  Jing Hou; Jie Xu; Ming Liu; Ruizhi Zhao; Hai-Bin Luo; Hengming Ke
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

6.  Crystal structures of SAMHD1 inhibitor complexes reveal the mechanism of water-mediated dNTP hydrolysis.

Authors:  Sarah J Caswell; Simone Kunzelmann; Elizabeth R Morris; Laurence H Arnold; Andrew G Purkiss; Geoff Kelly; Ian A Taylor
Journal:  Nat Commun       Date:  2020-06-23       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.